Long-term Impact of a “3 + 0” Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002–2014 | Zendy

Sanjay Jayasinghe | Zendy; Robert Menzies | Zendy; Clayton Chiu | Zendy; Cindy Toms | Zendy; Christopher C. Blyth | Zendy; Vicki Krause | Zendy; Peter McIntyre | Zendy

Open Access

Long-term Impact of a “3 + 0” Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002–2014

Author(s) -

Sanjay Jayasinghe,

Robert Menzies,

Clayton Chiu,

Cindy Toms,

Christopher C. Blyth,

Vicki Krause,

Peter McIntyre

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw720

Subject(s) - medicine , pneumococcal disease , pneumococcal conjugate vaccine , schedule , term (time) , pneumococcal infections , streptococcus pneumoniae , virology , immunology , microbiology and biotechnology , antibiotics , physics , biology , quantum mechanics , computer science , operating system

Australia introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replaced by 13-valent PCV (PCV13) in 2011, uniquely among high-income countries giving doses at 2, 4, and 6 months (3 + 0 schedule). Data on impact of a timely 3 + 0 PCV schedule with high coverage are sparse, with none for PCV13.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research